Alterity Therapeutics Files Director Interest Notice
Ticker: PRNAF · Form: 6-K · Filed: Apr 10, 2025 · CIK: 1131343
| Field | Detail |
|---|---|
| Company | Alterity Therapeutics Ltd (PRNAF) |
| Form Type | 6-K |
| Filed Date | Apr 10, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: director-filing, insider-activity, registration-statement
Related Tickers: ATHE
TL;DR
Alterity Therapeutics (ATHE) filed a 6-K for director interest changes; check for insider moves.
AI Summary
Alterity Therapeutics Ltd. filed a Form 6-K on April 10, 2025, incorporating by reference a Change of Director's Interest Notice. This filing is related to their ongoing registration statements on Form S-8 and Form F-3.
Why It Matters
This filing provides transparency regarding changes in director holdings, which can signal insider confidence or potential shifts in ownership structure.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of director interest changes and does not indicate immediate financial or operational risks.
Key Players & Entities
- Alterity Therapeutics Ltd. (company) — Registrant
- April 10, 2025 (date) — Filing Date
- Form 6-K (document) — Filing Type
- Change of Director's Interest Notice (document) — Exhibit
- Form S-8 (document) — Incorporated by Reference
- Form F-3 (document) — Incorporated by Reference
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report a Change of Director's Interest Notice and to incorporate it by reference into existing registration statements.
Which registration statements is this 6-K filing being incorporated into?
This Form 6-K is being incorporated by reference into Alterity Therapeutics' Registration Statements on Form S-8 (Files No. 333-251073, 333-248980, and 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417, and 333-250076).
What specific exhibit is included with this filing?
The specific exhibit included with this filing is '99.1 Change of Director’s Interest Notice x 3'.
What is the principal executive office address for Alterity Therapeutics Limited?
The principal executive office address for Alterity Therapeutics Limited is Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia.
Does Alterity Therapeutics file annual reports under Form 20-F or Form 40-F?
Alterity Therapeutics indicates that it files annual reports under cover of Form 20-F.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 10, 2025 regarding ALTERITY THERAPEUTICS LTD (PRNAF).